{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:36:56Z","timestamp":1790005016829,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00228-016-2020-6","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T01:29:29Z","timestamp":1456104569000},"page":"665-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation"],"prefix":"10.1007","volume":"72","author":[{"given":"Ivy","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Borland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Choukour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Jerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"2020_CR1","unstructured":"Tivicay\u00ae (dolutegravir) [package insert]. Research Triangle Park: ViiV Healthcare; 2014"},{"key":"2020_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","volume":"41","author":"MJ Reese","year":"2013","unstructured":"Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW (2013) In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353\u2013361","journal-title":"Drug Metab Dispos"},{"key":"2020_CR3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0091270010371113","volume":"51","author":"I Song","year":"2011","unstructured":"Song I, Min SS, Borland J, Lou Y, Chen S, Patel P, Ishibashi T, Piscitelli SC (2011) The effect of lopinavir\/ritonavir and darunavir\/ritonavir on the HIV integrase inhibitor S\/GSK1349572 in healthy participants. J Clin Pharmacol 51:237\u2013242","journal-title":"J Clin Pharmacol"},{"key":"2020_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2125.2011.03947.x","volume":"72","author":"I Song","year":"2011","unstructured":"Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, Piscitelli SC (2011) Effect of atazanavir and atazanavir\/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S\/GSK1349572. Br J Clin Pharmacol 72:103\u2013108","journal-title":"Br J Clin Pharmacol"},{"key":"2020_CR5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00228-014-1732-8","volume":"70","author":"I Song","year":"2014","unstructured":"Song I, Borland J, Chen S, et al. (2014) Effects of enzyme inducers efavirenz and tipranavir\/ritonavir on the pharmacokinetic of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol 70:1173\u20131179","journal-title":"Eur J Clin Pharmacol"},{"key":"2020_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"K Dooley","year":"2013","unstructured":"Dooley K, Sayre P, Borland J, et al. (2013) Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 62:21\u201327","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.seizure.2007.05.017","volume":"17","author":"C Kellinghaus","year":"2008","unstructured":"Kellinghaus C, Engbring C, Kovac S, et al. (2008) Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 17:27\u201333","journal-title":"Seizure"},{"key":"2020_CR8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1474-4422(05)70165-4","volume":"4","author":"JC McArthur","year":"2005","unstructured":"McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543\u2013555","journal-title":"Lancet Neurol"},{"key":"2020_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clpt.2006.08.013","volume":"80","author":"M Oscarson","year":"2006","unstructured":"Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA (2006) Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80:440\u2013456","journal-title":"Clin Pharmacol Ther"},{"key":"2020_CR10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","volume":"31","author":"E Spina","year":"1996","unstructured":"Spina E, Pisani F, Perucca E (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 31:198\u2013214","journal-title":"Clin Pharmacokinet"},{"key":"2020_CR11","unstructured":"Tegretol\u00ae (carbamazepine) [package insert]. East Hanover: Novartis; 2014"},{"key":"2020_CR12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.63.10_suppl_4.S3","volume":"63","author":"GD Anderson","year":"2004","unstructured":"Anderson GD (2004) Pharmacogenetics and enzyme induction\/inhibition properties of antiepileptic drugs. Neurology 63:S3\u2013S8","journal-title":"Neurology"},{"key":"2020_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D (2013) Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 54:11\u201327","journal-title":"Epilepsia"},{"key":"2020_CR14","unstructured":"Song I, Chen S, Piscitelli S, Min S. Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in INI-naive subjects. Abstract A-1573. Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2013; Denver"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2020-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2020-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T13:53:27Z","timestamp":1589637207000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2020-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2020-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]}}}